These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8805920)

  • 41. Health impact assessments in the European Union.
    Salay R; Lincoln P
    Lancet; 2008 Sep; 372(9641):860-1. PubMed ID: 18774419
    [No Abstract]   [Full Text] [Related]  

  • 42. Governance in EU illicit drugs policy.
    Edwards C; Galla M
    Int J Drug Policy; 2014 Sep; 25(5):942-7. PubMed ID: 25060612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. European Parliament gains ground in health.
    Rogers A
    Lancet; 1996 Apr; 347(9009):1180. PubMed ID: 8609773
    [No Abstract]   [Full Text] [Related]  

  • 44. Health policy and European law: closing the gaps.
    McKee M; Mossialos E
    Public Health; 2006 Oct; 120 Suppl():16-21; discussion 21-2. PubMed ID: 16979200
    [No Abstract]   [Full Text] [Related]  

  • 45. Health impact assessment: assessing opportunities and barriers to intersectoral health improvement in an expanded European Union.
    Lock K; McKee M
    J Epidemiol Community Health; 2005 May; 59(5):356-60. PubMed ID: 15831682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. European Union health policy and its implications for national convergence.
    Cucic S
    Int J Qual Health Care; 2000 Jun; 12(3):217-25. PubMed ID: 10894193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Policies and managerial guidelines for national cancer control programs.
    Rev Panam Salud Publica; 2002 Nov; 12(5):366-70. PubMed ID: 12587230
    [No Abstract]   [Full Text] [Related]  

  • 48. Subjective Perception of Safe Antibiotic Use in the Context of European Union Health Policy: Comparative Analysis.
    Tamasauskiene L; Tamasauskas D; Zilinskas G
    Popul Health Manag; 2018 Oct; 21(5):429. PubMed ID: 29851538
    [No Abstract]   [Full Text] [Related]  

  • 49. Regulation of biologicals in the European Union.
    Vicari G
    Dev Biol Stand; 1999; 100():145-8. PubMed ID: 10616185
    [No Abstract]   [Full Text] [Related]  

  • 50. The European union policy in the field of rare diseases.
    Montserrat Moliner A; Waligóra J
    Public Health Genomics; 2013; 16(6):268-77. PubMed ID: 24503587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Legalism and tobacco control in the EU.
    Jarman H
    Eur J Public Health; 2018 Nov; 28(suppl_3):26-29. PubMed ID: 30383253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Towards eradication of bovine tuberculosis in the European Union.
    Reviriego Gordejo FJ; Vermeersch JP
    Vet Microbiol; 2006 Feb; 112(2-4):101-9. PubMed ID: 16388921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Time for Sweden to recognize the right to health care in other European Union countries].
    Bernitz U; Lokrantz-Bernitz B
    Lakartidningen; 2005 Nov 28-Dec 4; 102(48):3709-10. PubMed ID: 16416951
    [No Abstract]   [Full Text] [Related]  

  • 54. A British perspective on alcohol problems in relation to European Community policy.
    Braine B
    Br J Addict; 1990 May; 85(5):677-81. PubMed ID: 2354285
    [No Abstract]   [Full Text] [Related]  

  • 55. Should the EU also wage war against cancer? And if so, how? Foreword and afterthoughts to this special issue on cancer control at the European level.
    Coebergh JW; Albreht T
    Eur J Cancer; 2008 Jul; 44(10):1341-4. PubMed ID: 18492608
    [No Abstract]   [Full Text] [Related]  

  • 56. Healthcare access and mobility between the UK and other European Union states: an 'implementation surplus'.
    Sheaff R
    Health Policy; 1997 Dec; 42(3):239-53. PubMed ID: 10176303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recommendations on cancer screening in the European union. Advisory Committee on Cancer Prevention.
    Eur J Cancer; 2000 Aug; 36(12):1473-8. PubMed ID: 10930794
    [No Abstract]   [Full Text] [Related]  

  • 58. [securPharm e. V. - a protective shield against falsified medicines].
    Bergen M; Hoferichter R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1255-1260. PubMed ID: 28929207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer control legislation and policy milestones in North Carolina.
    Wright JC; Greene LP; Aldrich TE
    N C Med J; 2001; 62(5):252-5. PubMed ID: 11570319
    [No Abstract]   [Full Text] [Related]  

  • 60. [Healthcare policy at the EU level: strategies for action of the European Commission exemplified by patient safety].
    Barth S; Godschalk B; Jonitz G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Jan; 58(1):10-5. PubMed ID: 25385039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.